NEW PATIENT APPOINTMENT PATIENT REFERRAL

Clinical Trial

Trial Protocol ID NT-175-201 *RIT*

Trial Description

***REFERRAL ONLY*** An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-175 in Human Leukocyte Antigen-A*02:01- Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsor

  • Neogene Therapeutics